Clinical Trials Logo

Systemic Mastocytosis clinical trials

View clinical trials related to Systemic Mastocytosis.

Filter by:

NCT ID: NCT01297777 Completed - Clinical trials for Systemic Mastocytosis

Imatinib in KIT-negative Systemic Mastocytosis

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Imatinib Mesylate therapy in patients with systemic mastocytosis lacking KIT mutations.

NCT ID: NCT00979160 Not yet recruiting - Clinical trials for Systemic Mastocytosis

Evaluation of Response of Dasatinib to Treat Mastocytosis

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).

NCT ID: NCT00918931 Terminated - Leukemia Clinical Trials

Obatoclax for Systemic Mastocytosis

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.

NCT ID: NCT00493129 Completed - Leukemia Clinical Trials

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

Start date: July 2004
Phase: Phase 2
Study type: Interventional

Primary Objective: 1. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: 1. To assess the safety of ONTAK in SM patients. 2. To evaluate the time to progression and duration of response following treatment with ONTAK.

NCT ID: NCT00449748 Completed - Clinical trials for Systemic Mastocytosis

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.

NCT ID: NCT00171912 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the effect on the malignancy.

NCT ID: NCT00109707 Completed - Clinical trials for Chronic Myelogenous Leukemia

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1) Group A - Imatinib failure only (arms 2, 3 and 4) - imatinib-resistant or intolerant CML - Chronic Phase (CP) - imatinib-resistant or intolerant CML - Accelerated Phase (AP) - imatinib-resistant or intolerant CML - Blast Crisis (BC) Group B - Imatinib and other TKI failure (arms 2, 3 and 4) - imatinib-resistant or intolerant CML - Chronic Phase (CP) - imatinib-resistant or intolerant CML - Accelerated Phase (AP) - imatinib-resistant or intolerant CML - Blast Crisis (BC) Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5) Systemic mastocytosis (Sm) (arm 6)